Catalyst Pharmaceuticals (CPRX) announced that its Board of Directors has authorized a new share repurchase program to repurchase up to $200 million of shares of Catalyst’s outstanding common stock between October 1, 2025, and December 31, 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- AI Analyst Is Bullish on These 3 “Strong Buy” Healthcare Stocks, 9/2/25
- Catalyst Pharma Settles Patent Dispute with Lupin
- Catalyst Pharmaceuticals announces settlement of FIRDAPSE patent litigation
- Catalyst Pharmaceuticals Reports Strong Q2 2025 Earnings
- Catalyst Pharma Updates Guidelines for SCLC Treatment